Anat Cohen-Dayag, Compugen CEO
December 19, 2023 07:10 AM ESTUpdated 07:46 AM
Deals
R&D

Com­pu­gen se­cures li­cens­ing deal with Gilead for IL-18 pro­tein an­ti­body can­cer pro­gram, with $60M up­front

Reynald Castañeda

Deputy Editor

Com­pu­gen is set to re­ceive an up­front pay­ment of $60 mil­lion from Gilead to kick­start an ex­clu­sive li­cens­ing deal for the biotech’s an­ti-in­ter­leukin-18 pro­tein bind­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times